Core Viewpoint - Belite Bio, Inc is actively participating in the Leerink Global Healthcare Conference, highlighting its focus on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs [1]. Company Overview - Belite Bio is a clinical-stage drug development company targeting degenerative retinal diseases, including Stargardt disease type 1 (STGD1) and geographic atrophy (GA) associated with advanced dry age-related macular degeneration (AMD) [3]. - The company's lead candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye [3]. - Belite Bio has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently conducting a Phase 2/3 trial (DRAGON II) in the same demographic, as well as a Phase 3 trial (PHOENIX) for subjects with GA [3].

Core Insights - Belite Bio, Inc. reported positive topline results from its pivotal Phase 3 DRAGON trial for tinlarebant, a potential first-in-class therapy for Stargardt disease, and plans to submit a New Drug Application (NDA) to the FDA in Q2 2026 [2][5][6] Financial Highlights - As of December 31, 2025, the company had $352.9 million in cash and cash equivalents, a significant increase from $31.7 million on December 31, 2024 [9] - The company completed a $402 million public offering, with net proceeds aimed at supporting commercialization preparation and pipeline development [8] - Research and development expenses for Q4 2025 were $14.6 million, up from $7.3 million in Q4 2024, primarily due to costs associated with the DRAGON II trial [10] - Selling, general, and administrative expenses for Q4 2025 were $13.5 million, compared to $4.2 million in Q4 2024, driven by increased share-based compensation and professional service fees [12] - The company reported a GAAP net loss of $25.3 million for Q4 2025, compared to a net loss of $10.1 million for the same period in 2024 [16] Clinical Development Highlights - Tinlarebant is an oral RBP4 antagonist that reduces vitamin A delivery to the eye, addressing the toxic accumulation in Stargardt disease and geographic atrophy [3][4] - The DRAGON trial demonstrated a 35.7% reduction in the growth rate of macular lesions in adolescent STGD1 patients, achieving statistical significance [6] - The DRAGON II trial has completed enrollment with 72 subjects, targeting a total of 60 subjects, and aims to facilitate a future NDA submission in Japan [5][6] Corporate Developments - The company has received multiple designations for tinlarebant, including Breakthrough Therapy and Fast Track in the U.S., and Orphan Drug Designation in multiple regions [4] - Belite Bio is focused on advancing treatments for degenerative retinal diseases with significant unmet medical needs, including STGD1 and geographic atrophy [19]

Core Viewpoint - Belite Bio, Inc is set to host a webcast on March 2, 2026, to discuss its financial results and provide a business update for Q4 and the full year ended December 31, 2025 [1]. Company Overview - Belite Bio is a clinical-stage drug development company focused on creating novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD) [3]. - The company's lead candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye [3]. - Belite Bio has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently conducting a Phase 2/3 trial (DRAGON II) in the same demographic, as well as a Phase 3 trial (PHOENIX) in subjects with GA [3]. Webcast Information - The webcast will take place on March 2, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) [2]. - A replay of the webcast will be available for approximately 90 days after the event [2].

Core Insights - Belite Bio, Inc is participating in the Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress to present findings related to its drug tinlarebant for Stargardt disease type 1 (STGD1) [1][2] Company Overview - Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases, including STGD1 and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD) [8] - The lead candidate, tinlarebant, is designed to reduce the accumulation of bisretinoid toxins in the eye, which are linked to retinal diseases [8] Upcoming Presentations - The company will present topline results from the Phase 3 DRAGON study of tinlarebant for adolescents with STGD1 during the APAO Congress [2][3] - An oral presentation is scheduled for February 6, 2026, and a sponsored lunch symposium will take place on February 7, 2026 [3] Exhibition Details - Belite Bio will have an exhibition booth at the APAO Congress from February 5-7, 2026, located at Hall 5E, Booth 5E-C03 [4] About Tinlarebant - Tinlarebant is an oral therapy that aims to reduce vitamin A-based toxins causing retinal disease in STGD1 and contributes to disease progression in GA [4] - The drug has received multiple designations, including Breakthrough Therapy and Fast Track in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan [4] About Stargardt Disease Type 1 (STGD1) - STGD1 is the most common inherited macular dystrophy, leading to central vision loss due to mutations in the ABCA4 gene [5] - There are currently no FDA-approved treatments for STGD1, highlighting the unmet medical need in this area [5]

Core Viewpoint - Belite Bio is nearing the commercialization of its leading drug candidate, tinlarebant, following positive results from a phase 3 trial, which significantly boosted its stock price by 12% [1][2]. Group 1: Drug Candidate and Trial Results - Tinlarebant met its primary endpoint in a phase 3 trial aimed at treating adolescents with Stargardt disease, a condition that can lead to loss of central vision [2][4]. - The drug demonstrated a nearly 36% reduction in lesion growth compared to a placebo, indicating its efficacy in slowing the progression of the disease [3]. - Minimal change in visual acuity was recorded after 24 months, further supporting the drug's potential [3]. Group 2: Company Statements and Future Plans - CEO Tom Lin highlighted that tinlarebant is the first oral treatment to show a clinically meaningful outcome in retinal degenerative disease [4]. - Belite Bio plans to submit New Drug Applications for tinlarebant in the first half of next year, indicating a proactive approach towards regulatory approval [4]. Group 3: Market Reaction and Financial Data - Following the announcement, Belite Bio's stock price rose to $16.58, reflecting a market capitalization of $5 billion [5]. - The stock's trading range for the day was between $130.06 and $154.99, with a 52-week range of $49.00 to $154.99 [6].